Pacific Horizon Ventures

ViaCyte, Inc. is a regenerative medicine company based in San Diego, California, that specializes in developing cell replacement therapies for diabetes. The company’s primary product candidates, VC-01 and VC-02, aim to treat type 1 diabetes by implanting pancreatic beta-cell precursors derived from stem cells within an encapsulation device. This innovative approach allows the implanted cells to produce insulin in response to blood glucose levels while minimizing the risk of immune rejection, thereby eliminating the need for immunosuppressants. ViaCyte's goal is to provide a long-term solution that can free both type 1 and type 2 diabetes patients from dependence on insulin and reduce associated complications such as hypoglycemia and cardiovascular issues. Founded in 1999, ViaCyte was previously known as Novocell, Inc., and changed its name in 2010. The company also operates an additional facility in Athens, Georgia.

Koronis Pharmaceuticals is a privately held biotechnology company based in Seattle, Washington, established in 1998. The company specializes in the development of antiviral therapeutics utilizing a unique mechanism known as Viral Decay Acceleration (VDA). Its lead product candidate, KP-1461, targets human immunodeficiency virus (HIV) and aims to improve treatment outcomes for patients. In addition to HIV, Koronis is also developing therapeutics for hepatitis C and respiratory syncytial virus (RSV). By focusing on innovative approaches to antiviral treatment, Koronis Pharmaceuticals seeks to enhance recovery rates and minimize complications associated with these serious viral infections.

ViaCyte, Inc. is a regenerative medicine company based in San Diego, California, that specializes in developing cell replacement therapies for diabetes. The company’s primary product candidates, VC-01 and VC-02, aim to treat type 1 diabetes by implanting pancreatic beta-cell precursors derived from stem cells within an encapsulation device. This innovative approach allows the implanted cells to produce insulin in response to blood glucose levels while minimizing the risk of immune rejection, thereby eliminating the need for immunosuppressants. ViaCyte's goal is to provide a long-term solution that can free both type 1 and type 2 diabetes patients from dependence on insulin and reduce associated complications such as hypoglycemia and cardiovascular issues. Founded in 1999, ViaCyte was previously known as Novocell, Inc., and changed its name in 2010. The company also operates an additional facility in Athens, Georgia.

iScience Surgical, Inc. is a privately-held company founded in 1999. It is developing high resolution imaging systems and microsurgical instruments for the treatment of glaucoma. The Company's products are designed to complement existing glaucoma surgical techniques and serve as a platform for a new generation of minimally invasive procedures. Glaucoma is a sight threatening circulatory disorder of the eye that affects approximately 4.2 million Americans and 69 million people worldwide. More than $2 billion is spent annually on glaucoma medications and treatments worldwide, the majority of which are unable to restore the eye's natural drainage process.

Argos Therapeutics, Inc. was a biotechnology company based in Durham, North Carolina, focused on developing personalized immunotherapies for cancer, infectious diseases, and autoimmune disorders. It utilized its proprietary Arcelis technology platform to create individualized treatments, including rocapuldencel-T, which was undergoing Phase III clinical trials for metastatic renal cell carcinoma, and AGS-004, in Phase II trials for human immunodeficiency virus. The company's product pipeline also included therapies aimed at transplant rejection and autoimmune conditions. Founded in 1997 and originally named Merix Bioscience, Argos Therapeutics aimed to address significant unmet medical needs in the field of immuno-oncology. However, on September 24, 2019, the company filed for Chapter 7 bankruptcy, leading to its cessation of operations.

TransMolecular, Inc. is a neuroscience biotechnology firm focused on discovering and developing innovative drugs for diagnosing and treating central nervous system diseases, particularly cancer and pain, where current treatment options are limited. Founded in 1996 and based in Birmingham, Alabama, the company has established robust technology platforms that support its product discovery and development efforts. It has received significant funding, including $9.6 million from venture capital sources and $1 million in Small Business Incentive Research grants from the National Institutes of Health. TransMolecular possesses over 25 patents and patent applications to safeguard its intellectual property and has exclusive licensing agreements with the University of Alabama at Birmingham Research Foundation and Yale University for its specialized technologies. The management team brings more than 75 years of combined experience in healthcare, pharmaceutical development, and related fields, underscoring the company’s commitment to creating safe and effective treatments for patients suffering from serious medical conditions.

iScience Interventional specializes in the discovery and development of microcatheter and imaging technologies aimed at enhancing ophthalmic care. The company focuses on a novel approach termed Interventional Ophthalmology, which involves microcatheter-based therapies that allow ophthalmologists to access various anatomical structures within the eye. These technologies facilitate the aspiration of ocular fluids and the delivery of sterile ophthalmic solutions, enabling targeted treatment for a range of ocular diseases. Additionally, iScience Interventional provides medical devices specifically designed for canaloplasty procedures, further contributing to advancements in the management of eye conditions.

iScience Surgical, Inc. is a privately-held company founded in 1999. It is developing high resolution imaging systems and microsurgical instruments for the treatment of glaucoma. The Company's products are designed to complement existing glaucoma surgical techniques and serve as a platform for a new generation of minimally invasive procedures. Glaucoma is a sight threatening circulatory disorder of the eye that affects approximately 4.2 million Americans and 69 million people worldwide. More than $2 billion is spent annually on glaucoma medications and treatments worldwide, the majority of which are unable to restore the eye's natural drainage process.

Inhibitex specializes in the development of antibody-based products aimed at preventing and treating bacterial and fungal infections. The company emphasizes the creation of small molecule antiviral compounds, with a particular focus on therapies for shingles, also known as herpes zoster, and chronic hepatitis C infections.

TransMolecular, Inc. is a neuroscience biotechnology firm focused on discovering and developing innovative drugs for diagnosing and treating central nervous system diseases, particularly cancer and pain, where current treatment options are limited. Founded in 1996 and based in Birmingham, Alabama, the company has established robust technology platforms that support its product discovery and development efforts. It has received significant funding, including $9.6 million from venture capital sources and $1 million in Small Business Incentive Research grants from the National Institutes of Health. TransMolecular possesses over 25 patents and patent applications to safeguard its intellectual property and has exclusive licensing agreements with the University of Alabama at Birmingham Research Foundation and Yale University for its specialized technologies. The management team brings more than 75 years of combined experience in healthcare, pharmaceutical development, and related fields, underscoring the company’s commitment to creating safe and effective treatments for patients suffering from serious medical conditions.

Proxim Wireless Corporation is a provider of high-speed wireless communications equipment and services that facilitate a range of applications, including voice, video, data, and mobility. Founded in 1982 and headquartered in San Jose, California, the company specializes in Wi-Fi, point-to-point, and point-to-multipoint 4G wireless network technologies. Its products are designed for various sectors, including transportation, video surveillance, education, healthcare, and retail, offering solutions for wireless Internet, backhaul, and video surveillance needs. Proxim Wireless serves a diverse customer base, including enterprises, service providers, government entities, and educational institutions, through a network of online retailers, distributors, value-added resellers, system integrators, and original equipment manufacturers across North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. As of mid-2018, Proxim Wireless operates as a subsidiary of SRA Holdings, Inc.